Literature DB >> 24966873

Histone mimics: digging down under.

Yiwei Lin1, Binhua P Zhou1.   

Abstract

Epigenetic deregulation is intimately associated with the development of human diseases. Intensive studies are currently underway to clarify the mechanism for the sake of achieving ideal diagnostic and therapeutic goals. It has been demonstrated that enzymes with histone-modifying activities can also target non-histone proteins, with the underlying mechanism remaining obscure. In this review, we focus on a novel histone mimicry strategy that may be wildly adapted during the non-histone substrate recognition process. Its potential clinical implications are also discussed.

Entities:  

Keywords:  epigenetics; histone mimicry

Year:  2013        PMID: 24966873      PMCID: PMC4067130          DOI: 10.1007/s11515-012-1211-5

Source DB:  PubMed          Journal:  Front Biol (Beijing)        ISSN: 1674-7984


  51 in total

1.  Azacitidine.

Authors:  Jean-Pierre J Issa; Hagop M Kantarjian; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2005-04       Impact factor: 84.694

Review 2.  Epigenetic therapy of cancer: past, present and future.

Authors:  Christine B Yoo; Peter A Jones
Journal:  Nat Rev Drug Discov       Date:  2006-01       Impact factor: 84.694

3.  The nucleosomal core histone octamer at 3.1 A resolution: a tripartite protein assembly and a left-handed superhelix.

Authors:  G Arents; R W Burlingame; B C Wang; W E Love; E N Moudrianakis
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-15       Impact factor: 11.205

Review 4.  Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis.

Authors:  Jing Yang; Robert A Weinberg
Journal:  Dev Cell       Date:  2008-06       Impact factor: 12.270

Review 5.  Epithelial-mesenchymal transitions in development and disease.

Authors:  Jean Paul Thiery; Hervé Acloque; Ruby Y J Huang; M Angela Nieto
Journal:  Cell       Date:  2009-11-25       Impact factor: 41.582

Review 6.  Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug.

Authors:  Paul A Marks; Ronald Breslow
Journal:  Nat Biotechnol       Date:  2007-01       Impact factor: 54.908

Review 7.  The role of epigenetics in the pathology of diabetic complications.

Authors:  Louisa M Villeneuve; Rama Natarajan
Journal:  Am J Physiol Renal Physiol       Date:  2010-05-12

Review 8.  The epigenomics of cancer.

Authors:  Peter A Jones; Stephen B Baylin
Journal:  Cell       Date:  2007-02-23       Impact factor: 41.582

9.  Unbiased proteomic screen for binding proteins to modified lysines on histone H3.

Authors:  Doug W Chan; Yi Wang; Meng Wu; Jiemin Wong; Jun Qin; Yingming Zhao
Journal:  Proteomics       Date:  2009-05       Impact factor: 3.984

Review 10.  Epigenetic modifications as therapeutic targets.

Authors:  Theresa K Kelly; Daniel D De Carvalho; Peter A Jones
Journal:  Nat Biotechnol       Date:  2010-10       Impact factor: 54.908

View more
  1 in total

1.  Doxorubicin enhances Snail/LSD1-mediated PTEN suppression in a PARP1-dependent manner.

Authors:  Yiwei Lin; Tiebang Kang; Binhua P Zhou
Journal:  Cell Cycle       Date:  2014-03-25       Impact factor: 4.534

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.